BetterAlt’s latest retail expansion is placing its Ayurvedic-inspired wellness products in 425 Sprouts Farmers Market locations across the U.S., reinforcing consumer demand for natural supplements that combine traditional remedies with modern science-backed formulations.
BetterAlt’s latest retail expansion is placing its Ayurvedic-inspired wellness products in 425 Sprouts Farmers Market locations across the U.S., reinforcing consumer demand for natural supplements that combine traditional remedies with modern science-backed formulations.
Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support.
Wonderfeel’s 2025 Youngr™ update features a 900mg stabilized NMN dose with antioxidant co-factors, formulated to align with consumer interest in bioavailable, non-synthetic NAD+ wellness support.
As consumers turn to ingredient-based mental clarity tools, Brain Defender emphasizes formulation transparency and non-clinical support in the evolving cognitive wellness space.
As consumers turn to ingredient-based mental clarity tools, Brain Defender emphasizes formulation transparency and non-clinical support in the evolving cognitive wellness space.
MORTON GROVE, Ill., July 3, 2025 /PRNewswire/ -- Lifeway Foods, Inc. (NASDAQ: LWAY) ("Lifeway" or the "Company"), a leading U.S. supplier of Kefir and fermented...
Projected to grow at a 6.4% CAGR, the global pet supplements market will hit $5 billion by 2034. Rising pet ownership and focus on pet wellness, supported by AI-driven personalized nutrition and eco-friendly practices, are key growth drivers. The market thrives across North America, Europe, and Asia-Pacific.
Projected to grow at a 6.4% CAGR, the global pet supplements market will hit $5 billion by 2034. Rising pet ownership and focus on pet wellness, supported by AI-driven personalized nutrition and eco-friendly practices, are key growth drivers. The market thrives across North America, Europe, and Asia-Pacific.
Vancouver, Canada, July 03, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has received Institutional Review Board (IRB) approval from Tel Aviv Sourasky Medical Center (TASMC) in Tel Aviv, Israel, for its ongoing Phase 1/2a clinical trial evaluating CMND-100, a proprietary MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD). This approval will enable patient enrollment at TASMC, a leading clinical site in Israel, prior to commencing this first-in-human trial at the site.
New York City, NY, July 03, 2025 (GLOBE NEWSWIRE) -- In 2025, Nixol, a plant-based dietary supplement, made its debut in the United Kingdom and Ireland, marking a significant entry into the wellness supplement market. Designed to support healthy weight management, boost metabolism, and curb cravings, Nixol has positioned itself as a natural, vegan-friendly alternative to traditional weight loss solutions. Unlike products that rely on synthetic stimulants or restrictive diets, Nixol leverages a blend of carefully selected, science-backed ingredients to promote sustainable fat reduction and overall well-being. This article provides an in-depth exploration of Nixol’s launch, its formulation, claims, scientific backing, customer feedback, and the broader context of its market entry, while critically examining its potential effectiveness and limitations. Visit Official Website